NCT07205796View on ClinicalTrials.gov

A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

480

Participants

Timeline

Start Date

May 1, 2026

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

HZ Vaccine (IN001)

Formulation for injection

BIOLOGICAL

Shingrix

Sterile suspension for injection

All Listed Sponsors

lead

Shenzhen Shenxin Biotechnology Co., Ltd

INDUSTRY